Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814905 | 1.00 | MAPT (0.41) | MAPTTDP1F11UCHL1USP30 | |
| SCHEMBL3817098 | 0.83 | F11 (0.45) | MAPTF11NR1I3TP53GAA | |
| SCHEMBL2746114 | 0.83 | KMT2A (0.46) | MAPTTDP1MEN1ALDH1A1RAB9A | |
| SCHEMBL2746115 | 0.83 | KMT2A (0.46) | MAPTTDP1MEN1ALDH1A1RAB9A | |
| SCHEMBL14392135 | 0.77 | MAPT (0.43) | MAPTF11UCHL1USP30HSD17B10 | |
| SCHEMBL3819022 | 0.76 | PTGS2 (0.43) | MAPTTDP1NR1I3GAATHRB | |
| SCHEMBL3819019 | 0.76 | PTGS2 (0.43) | MAPTTDP1NR1I3GAATHRB | |
| SCHEMBL13839386 | 0.72 | GABRG2 (0.45) | MAPTNR1I3TP53GAATHRB | |
| SCHEMBL13024498 | 0.71 | MEN1 (0.43) | HSD17B10MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL3755520 | 0.71 | MAPT (0.53) | MAPTTDP1GAAHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2013218-A2 | RAF INHIBITORS AND THEIR USES | ARQULE, INC. (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | MAPT 3810/4885TDP1 2009/4885F11 1819/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | MAPT 3899/4885TDP1 2065/4885F11 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.